HAMLET BIOPHARMA Aktie

 

[image]  Hamlet BioPharma AB, an innovative pharmaceutical company developing new therapies for cancer and infections, announces that the company presented its latest advances at the Financial Stockholm event on March 26, 2026.   Financial Stockholm is a central meeting place for companies and investors who want to stay up to date on the latest trends in the stock market. The event attracts both professional players and private investors from all over Sweden.   Please see the presentation at: https://www.youtube.com/watch?v=5VLDg_2kfD8       For more information...

[image]Hamlet BioPharma invites you to our monthly investors' meeting to be held on the 18th of March 2026, at 12:00. Please click on the link below to participate in the meeting https://us06web.zoom.us/j/87443477663?pwd=3QfpaU8RvYGIxlqF2o8uDEmIpX2mwM.1   For further information, please contact Catharina Svanborg, Chairman of the Board, Hamlet BioPharma AB, +46 709 42 65 49, catharina.svanborg@hamletpharma.com Jakob Testad, CEO, Hamlet BioPharma AB, +46 708 48 42 10, jakob.testad@hamletbiopharma.com...

[image]  Hamlet BioPharma AB (Hamlet), a clinical‑stage biopharmaceutical company advancing targeted oncological and other therapies, today announces that its wholly owned subsidiary Alpha1H BC AB (A1HB) its collaborator Linnane Pharma AB (Linnane) and Hamlet have signed a non-binding Letter of Intent (LoI) with an undisclosed company specializing in uro-oncology based in northern Germany. The purpose is to outline terms and conditions for the completion of development and for global commercialization of Alpha 1H in the field of bladder cancer. Alpha 1H is being developed by Hamlet...

[image] Hamlet BioPharma invites you to our February investors' meeting to be held on the 13th of February 2026, at 12:00. Please click on the link below to participate in the meeting https://youtube.com/live/qstpMe2jhKI?feature=share     For further information, please contact Catharina Svanborg, Chairman of the Board, Hamlet BioPharma AB, +46 709 42 65 49, catharina.svanborg@hamletpharma.com Jakob Testad, CEO, Hamlet BioPharma AB, +46 708 48 42 10, jakob.testad@hamletbiopharma.com...

Hamlet BioPharma has signed an agreement with the Korean biotech company ImmunoForge, to develop novel administration technology for the peptide drug NZX, for use in patients with tuberculosis. Tuberculosis is a major cause of mortality in all parts of the world and treatment options are becoming more limited, due to escalating antibiotic resistance. The antimicrobial peptide NZX is being developed as a drug candidate for pulmonary tuberculosis treatment, in collaboration with Hamlet BioPharma. The new, peptide-based drug has shown promising treatment effects against lung tuberculosis in...

Welcome to Hamlet BioPharma's monthly digital meeting on January 21 at 12:00, held the same day as the Davos Summit discusses ''The Fragile Future of Antibiotics. '' [image] As stated in the Davos Summit Program: “Antimicrobial resistance (AMR) is already undermining modern medicine. As superbugs evolve faster than new treatments can be developed, once-manageable infections are becoming harder to cure, threatening everything from surgery to cancer care. How can we ensure global access to life-saving antibiotics while preserving their effectiveness for generations to come?” https://www....

OPENING REMARKS  The 2024-2025 financial year was extremely productive for Hamlet BioPharma and this trend continued into the first quarter of the financial year 2025-2026. The company has successfully completed Phase II studies of cancer and infection, secured production of drugs for Phase III studies, expanded the patent portfolio and secured financing, both short-term and long-term. These achievements identify the company as a mature pharmaceutical company and pave the way for commercialization and efficient development of the rich project portfolio of promising new drug candidates....

HAMLET BioPharma, a clinical‑stage biopharmaceutical company advancing targeted oncological and other therapies, today announced it has received written feedback from the U.S. Food and Drug Administration (FDA) supporting a pivotal development path for Alpha1H, a first‑in‑class neoadjuvant therapy for patients with low‑risk non–muscle invasive bladder cancer (NMIBC). [En bild som visar text, skärmbild, Färggrann, grafisk design AI-genererat innehåll kan vara felaktigt.] This latest interaction with the US FDA follows the previous successful face-to-face interaction with the Agency last...

[image] One of the most comprehensive studies ever conducted in childhood urinary tract infection shows that a chaotic immune response causes symptoms and damages the tissues — not the bacteria themselves, please see press releases April 9th and October 24th 2025. Investor Relations Update   Summary An international clinical study in infants experiencing their first febrile urinary tract infection included more than 160 infants in Sweden and Singapore. Genome wide technology and a strict clinical pathway makes this one of the most detailed studies ever performed and...

New molecular concepts for the treatment of bacterial infections were presented at the National Infection Biology meeting, held on October 20-21.  Scientists collaborating with Hamlet BioPharma AB, the pharmaceutical company specializing in the development of drugs for cancer and infections, have developed several drug candidates and demonstrated their potent treatment effects. The discoveries suggest a transformative shift in infectious disease management, built on the discovery of molecules that target the disease response of the host rather than the pathogen itself. [image]...

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces detailed information from the large-scale international study in infants, communicated on April 9, 2025. The large, international study, conducted by scientists and clinicians in Sweden and Singapore involved over 160 infants with their first febrile urinary tract infection and provides one of the most comprehensive molecular data sets ever generated for acute pyelonephritis. The advanced methodology and the way the clinical study was performed reshape the understanding...

Hamlet BioPharma invites you to our September investors' meeting to be held on the 25th of September 2025, at 12:00. Please click on the link below to participate in the meeting https://us06web.zoom.us/j/88423865694?pwd=KGFkXOkqalYZbtCLGeliTibarJCeEI.1   For further information, please contact Catharina Svanborg, CEO, Hamlet BioPharma AB, +46 709 42 65 49, catharina.svanborg@hamletpharma.com Jakob Testad, CFO, Hamlet BioPharma AB, +46 708 48 42 10, jakob.testad@hamletbiopharma.com      www.hamletbiopharma.com...

Hamlet BioPharma, ticker Hamlet, the pharmaceutical company specializing in the development of drugs for cancer and infections, today announces the successful production of a first batch of Alpha1H, the drug candidate targeting Bladder Cancer, at Phase III quality. The batch is now undergoing final evaluation steps, before release for clinical use. [image]The clinical trial program in patients with bladder cancer has proceeded successfully, showing significant treatment effects and low toxicity in treated patients. Large-scale manufacturing of Alpha1H at Good Manufacturing Practice (GMP)...

Hamlet BioPharma, a global leader in the treatment of cancer and infections announces the successful granting of new patents, strengthening its intellectual property portfolio, reaffirming its position at the forefront of technological innovation. Five new patents in Australia, China, India, Japan, and the US have been granted since the press release on 7 April 2025, which announced three new patents. The newly granted patents cover breakthroughs in the HAMLET family of drug candidates which effectively kill cancer cells and growing tumor tissue with high precision, as well as the company's...

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces the PhD thesis defense by Samudra Sabari, M. Sc. The defense will take place at 1 pm, Belfragesalen, BMC D15, Lund. The Faculty opponent will be Professor Boris Zhivotovsky, Karolinska Institutet. The thesis is based on four papers, three of which are published in peer reviewed international journals and one manuscript.     The first paper describes a new concept for cell death, where Alpha1H targets a major membrane system (ER) in tumor cells that stretches from...

OPENING REMARKS The fiscal year of 2024-2025 has been extremely productive in Hamlet BioPharma, including the fourth quarter (Q4). The company has successfully completed Phase II studies of cancer and infection, secured drug production  in preparation for Phase III trials, extended the patent portfolio and secured funding, short and long term.  These advances identify the company as a mature drug development organization, setting the stage for the commercialization of the advanced projects and efficient development of the rich project portfolio of validated and promising new drug...

LUND, Sweden, Aug. 21, 2025 /PRNewswire/ -- Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces the completion of the successful Phase II clinical trial of the company's drug candidate Alpha1H in patients with cancer......